Aliases & Classifications for Phobic Disorder

MalaCards integrated aliases for Phobic Disorder:

Name: Phobic Disorder 12 15
Phobic Anxiety Disorder 73

Classifications:



Summaries for Phobic Disorder

Disease Ontology : 12 An anxiety disorder where fear and anxiety are triggered by a specific stimulus or situation.

MalaCards based summary : Phobic Disorder, also known as phobic anxiety disorder, is related to social phobia and phobia, specific. An important gene associated with Phobic Disorder is MAOA (Monoamine Oxidase A), and among its related pathways/superpathways are Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways and Serotonergic synapse. The drugs Norepinephrine and Citalopram have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and thyroid, and related phenotypes are behavior/neurological and cardiovascular system

Related Diseases for Phobic Disorder

Diseases related to Phobic Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Related Disease Score Top Affiliating Genes
1 social phobia 32.9 HTR1A MAOA SLC6A4
2 phobia, specific 31.2 COMT MAOA NBAS
3 depression 30.0 HTR1A MAOA SLC6A4
4 substance dependence 30.0 MAOA OPRK1 SLC6A4
5 alcohol dependence 28.6 COMT HTR1A MAOA OPRK1 SLC6A4
6 agoraphobia 28.5 HTR1A MAOA OPRK1 PIR PTK7 RGS2
7 anxiety 28.3 COMT HTR1A MAOA PTK7 SLC6A4
8 panic disorder 26.3 COMT GLRB HTR1A MAOA PTK7 RGS2
9 schizoid personality disorder 10.6 HTR1A PIR
10 atypical depressive disorder 10.6 MAOA SLC6A4
11 obsessive-compulsive personality disorder 10.6 PIR SLC6A4
12 pathological gambling 10.5 MAOA SLC6A4
13 psychosexual disorder 10.5 HTR1A SLC6A4
14 periodic limb movement disorder 10.5 HTR1A SLC6A4
15 intermittent explosive disorder 10.4 HTR1A SLC6A4
16 dysthymic disorder 10.4 MAOA PIR SLC6A4
17 kleptomania 10.3 HTR1A MAOA SLC6A4
18 serotonin syndrome 10.3 HTR1A MAOA SLC6A4
19 migraine without aura 10.3 HTR1A SLC6A4
20 endogenous depression 10.3 MAOA SLC6A4
21 neonatal abstinence syndrome 10.2 COMT OPRK1
22 dystonia 1, torsion, autosomal dominant 10.2 COMT MAOA
23 fibromyalgia 10.2 COMT SLC6A4
24 separation anxiety disorder 10.1 NBAS PIR
25 sudden infant death syndrome 10.1 HTR1A MAOA SLC6A4
26 opioid addiction 10.1 COMT OPRK1
27 opiate dependence 10.1 OPRK1 SLC6A4
28 oppositional defiant disorder 10.1 COMT MAOA SLC6A4
29 antisocial personality disorder 10.1 COMT MAOA SLC6A4
30 paranoid schizophrenia 10.1 COMT MAOA SLC6A4
31 early-onset schizophrenia 10.1 COMT MAOA SLC6A4
32 conduct disorder 10.0 COMT MAOA SLC6A4
33 premature ejaculation 10.0 COMT HTR1A SLC6A4
34 bulimia nervosa 10.0 COMT MAOA SLC6A4
35 dyspepsia 10.0 HTR1A SLC6A4
36 substance abuse 10.0 COMT MAOA SLC6A4
37 alexithymia 10.0 COMT HTR1A SLC6A4
38 post-traumatic stress disorder 10.0 COMT MAOA SLC6A4
39 bipolar i disorder 10.0 COMT HTR1A SLC6A4
40 schizophrenia 10.0
41 psychotic disorder 9.9 COMT HTR1A SLC6A4
42 generalized anxiety disorder 9.9 HTR1A MAOA RGS2 SLC6A4
43 aging 9.8
44 anorexia nervosa 9.8
45 brunner syndrome 9.7 COMT HTR1A MAOA SLC6A4
46 postpartum depression 9.7 COMT HTR1A MAOA SLC6A4
47 borderline personality disorder 9.7 COMT HTR1A MAOA SLC6A4
48 mental depression 9.7 COMT HTR1A MAOA SLC6A4
49 cocaine dependence 9.7 OPRK1 SLC6A4
50 personality disorder 9.7 COMT HTR1A MAOA SLC6A4

Graphical network of the top 20 diseases related to Phobic Disorder:



Diseases related to Phobic Disorder

Symptoms & Phenotypes for Phobic Disorder

MGI Mouse Phenotypes related to Phobic Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.7 COMT GLRB HTR1A MAOA OPRK1 RGS2
2 cardiovascular system MP:0005385 9.5 COMT GLRB HTR1A MAOA PTK7 RGS2
3 nervous system MP:0003631 9.23 GLRB HTR1A MAOA OPRK1 PTK7 RGS2

Drugs & Therapeutics for Phobic Disorder

Drugs for Phobic Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 245)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Norepinephrine Approved Phase 4,Phase 3,Not Applicable 51-41-2 439260
2
Citalopram Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 59729-33-8 2771
3
Ethanol Approved Phase 4,Phase 2,Phase 3,Not Applicable 64-17-5 702
4
Cycloserine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 68-41-7 401 6234
5
Lidocaine Approved, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 137-58-6 3676
6
Sertraline Approved Phase 4,Phase 3,Phase 2,Not Applicable 79617-96-2 68617
7
Dopamine Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-61-6, 62-31-7 681
8
Olanzapine Approved, Investigational Phase 4,Phase 3 132539-06-1 4585
9 Piracetam Approved, Investigational Phase 4,Phase 2 7491-74-9
10
Tiagabine Approved, Investigational Phase 4 115103-54-3 60648
11
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
12
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
13
Propranolol Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 525-66-6 4946
14
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
15
Paroxetine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61869-08-7 43815
16
Topiramate Approved Phase 4 97240-79-4 5284627
17
Vortioxetine Approved, Investigational Phase 4 508233-74-7 9966051
18
Acetylcholine Approved Phase 4 51-84-3 187
19
Tetracaine Approved, Vet_approved Phase 4 94-24-6 5411
20 Etiracetam Investigational Phase 4,Phase 2 33996-58-6
21 Analgesics Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
22 Renal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Cholinergic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
25 Serotonin 5-HT1 Receptor Agonists Phase 4,Not Applicable
26 Muscarinic Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
27 Cholinergic Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
28 Serotonin Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
29 Serotonin Uptake Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
30 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
31 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
32 Parasympatholytics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
33 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
34 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Antidepressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
37 Antidepressive Agents, Second-Generation Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
38 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Antiparkinson Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
40 Psychotropic Drugs Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
41 Antitubercular Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
44 Quetiapine Fumarate Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 111974-72-2
45 Desvenlafaxine Succinate Phase 4 386750-22-7
46 Adrenergic Agents Phase 4,Phase 3,Phase 2,Not Applicable
47 Central Nervous System Stimulants Phase 4,Not Applicable
48 Adrenergic Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
49 Adrenergic beta-Antagonists Phase 4,Phase 2,Phase 3,Not Applicable
50 GABA Agents Phase 4,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 443)
# Name Status NCT ID Phase Drugs
1 The Use of Quetiapine (Seroquel) in the Treatment of Social Phobia: Public Speaking Environment Completed NCT00407199 Phase 4 quetiapine
2 RCT of Cognitive Therapy, Paroxetine, Combined CT and Paroxetine and Placebo Completed NCT00184106 Phase 4 Seroxat, Cognitive therapy, Seroxat+ cognitive therapy
3 D-Cycloserine Enhancement of Exposure in Social Phobia Completed NCT00633984 Phase 4 D-Cycloserine;Placebo
4 Improving Treatment Outcomes in Pharmacotherapy of Generalized Social Anxiety Disorder Completed NCT00282828 Phase 4 Sertraline;Venlafaxine;Placebo;Clonazepam
5 Nefazodone in the Treatment of Social Phobia Completed NCT00231348 Phase 4 Nefazodone
6 12-Week Study of Pristiq (Desvenlafaxine) Social Anxiety Disorder Completed NCT01316302 Phase 4 Pristiq;Placebo
7 Effectiveness of Levetiracetam in the Treatment of Body Dysmorphic Disorder Completed NCT00265109 Phase 4 Levetiracetam
8 Study To Evaluate The Effects Of Gabitril™ In Patients With Social Anxiety Disorder Completed NCT00208741 Phase 4 Gabitril
9 Changes of Cerebral Glucose Metabolism and After 12 Weeks of Escitalpram Treatment in Panic Disorder Completed NCT00767871 Phase 4 Lexapro
10 Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism Completed NCT00246441 Phase 4 Paroxetine;Placebo
11 Adjunctive Quetiapine in the Treatment of Refractory Social Anxiety Disorder in Adults Completed NCT01224067 Phase 4 Quetiapine
12 Escitalopram in Patients With Social Anxiety Disorder Completed NCT00902226 Phase 4 Escitalopram
13 Phase 4 Study to Evaluate Efficacy of Paliperidone Extended-Release(ER) in Schizophrenic Participants Completed NCT00761605 Phase 4 Paliperidone
14 Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety Completed NCT00177008 Phase 4 Aripiprazole
15 Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder Completed NCT00190879 Phase 4 Atomoxetine hydrochloride;placebo
16 Primary Care Intervention Strategy for Anxiety Disorders Completed NCT00347269 Phase 4 Psychotropic medication optimization
17 Acamprosate in Alcoholics With Comorbid Anxiety or Depression Completed NCT00330174 Phase 4 Acamprosate
18 The Study of Cognitive Rehabilitation Effectiveness for Mild Traumatic Brain Injury Completed NCT01339806 Phase 4
19 Efficacy Study of Paliperidone to Evaluate Subjective Change in Well-being and Drug Attitude in Schizophrenic Participants Completed NCT00784238 Phase 4 Paliperidone
20 Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity Completed NCT01863459 Phase 4 Lisdexamfetamine Dimesylate;placebo
21 Paliperidone Extended Release(ER) Effectiveness Study to Evaluate the Objective Symptom Change and Symptomatic Remission Completed NCT00761579 Phase 4 Paliperidone
22 Secondary Prevention With Paroxetine vs. Placebo in Subthreshold Posttraumatic Stress Disorder (PTSD) Completed NCT00560612 Phase 4 Paroxetine;Placebo
23 Efficacy of Adding Topiramate to Current Treatment in Treatment-Resistant Generalized Social Phobia (GSP) Recruiting NCT00182455 Phase 4 Topiramate;Placebo
24 Treatments for Anxiety: Meditation and Escitalopram Recruiting NCT03522844 Phase 4 Escitalopram
25 The Effects of Antipsychotic Drugs on Brain Metabolism in Healthy Individuals Recruiting NCT02536846 Phase 4 Olanzapine
26 Comparison of Routine IM Influenza Immunization and Administration by Jet-injector (Med-Jet H4™) in Healthy Young Adults Active, not recruiting NCT03150537 Phase 4
27 Brief Intervention to Reduce Fear of Public Speaking Active, not recruiting NCT02790736 Phase 4 propranolol;Placebo
28 Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder Active, not recruiting NCT02294305 Phase 4 Vortioxetine;Placebo
29 A Study to Evaluate the Benefit of Octagam 5%® in Subjects With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) Active, not recruiting NCT03348618 Phase 4
30 Effect of Including Synera® in Discussions on Dialysis Access Conversion in Patients With Needle Phobias Terminated NCT01623583 Phase 4
31 Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders Terminated NCT00182533 Phase 4 Sertraline;Placebo
32 A Study of the Efficacy of Botox in the Treatment of Social Anxiety Disorder Terminated NCT03078270 Phase 4 botulinum toxin A
33 Transfer of Manualized Cognitive-Behavioral Therapy (CBT) for Social Phobia Into Clinical Practice Unknown status NCT01388231 Phase 2, Phase 3
34 Study of Escitalopram in the Treatment of Specific Phobia Completed NCT00121069 Phase 2, Phase 3 Escitalopram
35 Treatment of Childhood Social Phobia Completed NCT00043537 Phase 3 Fluoxetine;Pill Placebo
36 Residential Cognitive and Interpersonal Therapy for Social Phobia Completed NCT00326430 Phase 2, Phase 3
37 A Comparison Between Internet Therapy and Group Therapy for Social Phobia - A Trial Using Cognitive Behavioural Therapy Completed NCT00564967 Phase 3
38 Treatment of Social Phobia and Panic Disorder in Adults Completed NCT00619138 Phase 3
39 Effect of D-cycloserine Plus Cognitive Behavioral Therapy on People With Social Phobia Completed NCT00515879 Phase 3 D-cycloserine;Placebo
40 Yohimbine to Enhance Cognitive Behavioral Therapy (CBT) for Social Anxiety Completed NCT00958880 Phase 3 Yohimbine Hydrochloride;Sugar Pill
41 D-Cycloserine to Enhance Cognitive Behavioral Therapy (CBT) for Acrophobia Completed NCT01102803 Phase 3 D-Cycloserine;Placebo
42 Facilitation of Fear Extinction With Yohimbine Hydrochloride in Phobic Participants Completed NCT00734422 Phase 2, Phase 3
43 Noradrenergic Manipulation and Virtual Reality Exposure Therapy in Phobic Participants Completed NCT02007694 Phase 2, Phase 3
44 Long-term Study Of Paroxetine in Women and Men Completed NCT00264654 Phase 3 BRL29060A;paroxetine hydrochloride hydrate
45 Social Anxiety Disorder Study Of Paroxetine Completed NCT00318669 Phase 3 Paroxetine hydrochloride hydrate
46 Flushing in Social Anxiety Disorder on Seroquel Completed NCT00773162 Phase 3 Seroquel;Sugar Pill
47 Child and Adolescent Anxiety Disorders (CAMS) Completed NCT00052078 Phase 3 Sertraline (SRT);Placebo
48 Efficacy and Tolerability of Atomoxetine (Strattera) in Adult Patients With Generalized Social Anxiety Disorder Completed NCT00260533 Phase 2, Phase 3 atomoxetine;placebo
49 Adding Cognitive Behavioral Therapy to Drug Treatment for Social Anxiety Disorder Completed NCT00074802 Phase 3 Paroxetine
50 Quetiapine in Social Anxiety Disorder Completed NCT00215254 Phase 2, Phase 3 quetiapine

Search NIH Clinical Center for Phobic Disorder

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Phobic Disorder

Anatomical Context for Phobic Disorder

MalaCards organs/tissues related to Phobic Disorder:

41
Brain, Eye, Thyroid, Colon, Testes, Skin, Ovary

Publications for Phobic Disorder

Articles related to Phobic Disorder:

(show all 19)
# Title Authors Year
1
Choking Phobia : An Uncommon Phobic Disorder, Treated with Behavior Therapy : A Case Report and Review of the Literature. ( 28638212 )
2016
2
[Hypnosis for anxiety and phobic disorders: A review of clinical studies]. ( 26944812 )
2016
3
Validation of the diagnoses of panic disorder and phobic disorders in the US National Comorbidity Survey Replication Adolescent (NCS-A) supplement. ( 21495110 )
2011
4
Genetic association between BDNF gene polymorphisms and phobic disorders: a case-control study among mainland Han Chinese. ( 21295349 )
2011
5
The effectiveness of anxiety treatment on alcohol-dependent patients with a comorbid phobic disorder: a randomized controlled trial. ( 15897725 )
2005
6
Temporal relationship between the age of onset of phobic disorders and development of substance dependence in adolescent psychiatric patients. ( 15283954 )
2004
7
[Obsessive-phobic disorder typology in schizophrenia]. ( 11915702 )
2002
8
A polymorphic genomic duplication on human chromosome 15 is a susceptibility factor for panic and phobic disorders. ( 11509185 )
2001
9
[Obsessive-phobic disorders with the phenomena of mysophobia in slowly progressing schizophrenia]. ( 11243027 )
2001
10
Social and personal resources and the prevalence of phobic disorder in a community population. ( 10883724 )
2000
11
The longitudinal study of phobic disorder in a community sample from early to late adolescence. ( 11018436 )
2000
12
Phobic disorder, psychotherapy, and risk-taking: an economic perspective. ( 10180917 )
1998
13
Frequency of phobic disorder in a community sample of young adolescents. ( 7559315 )
1995
14
Role of thymic hormones in neuroimmunomodulation. Their use in patients with phobic disorders. ( 1776534 )
1991
15
Administration of thymopentin to patients with phobic disorders improves depressed phagocytic functions. ( 2092042 )
1990
16
Double-blind comparison of alprazolam and adinazolam for panic and phobic disorders. ( 2651489 )
1989
17
Phobic disorders and anxiety states: how do they differ? ( 2649065 )
1989
18
Delineation of anxiety and phobic disorders responsive to monoamine oxidase inhibitors: implications for classification. ( 6429129 )
1984
19
Is anorexia nervosa a phobic disorder? A psychophysiological enquiry. ( 7417632 )
1980

Variations for Phobic Disorder

Copy number variations for Phobic Disorder from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 94765 15 70400000 76100000 Copy number LOXL1 phobic disorder

Expression for Phobic Disorder

Search GEO for disease gene expression data for Phobic Disorder.

Pathways for Phobic Disorder

GO Terms for Phobic Disorder

Cellular components related to Phobic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.55 GLRB HTR1A OPRK1 PTK7 SLC6A4
2 dendrite GO:0030425 9.26 COMT GLRB HTR1A OPRK1
3 neuron projection GO:0043005 8.92 GLRB OPRK1 RGS2 SLC6A4

Biological processes related to Phobic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.58 GLRB HTR1A OPRK1
2 regulation of sensory perception of pain GO:0051930 9.37 COMT OPRK1
3 vasoconstriction GO:0042310 9.32 HTR1A SLC6A4
4 neurotransmitter catabolic process GO:0042135 9.26 COMT MAOA
5 catecholamine metabolic process GO:0006584 9.16 COMT MAOA
6 behavior GO:0007610 8.96 HTR1A OPRK1
7 dopamine catabolic process GO:0042420 8.62 COMT MAOA

Sources for Phobic Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....